North Point Portfolio Managers Corp OH Has $18.22 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

North Point Portfolio Managers Corp OH lowered its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.8% in the second quarter, HoldingsChannel reports. The firm owned 17,338 shares of the biopharmaceutical company’s stock after selling 678 shares during the period. Regeneron Pharmaceuticals makes up 3.2% of North Point Portfolio Managers Corp OH’s portfolio, making the stock its 8th largest position. North Point Portfolio Managers Corp OH’s holdings in Regeneron Pharmaceuticals were worth $18,223,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Stephens Consulting LLC bought a new position in Regeneron Pharmaceuticals during the second quarter worth about $26,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Regeneron Pharmaceuticals by 23.8% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock worth $525,804,000 after acquiring an additional 96,266 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 1.1% during the second quarter. Principal Financial Group Inc. now owns 170,264 shares of the biopharmaceutical company’s stock worth $178,953,000 after acquiring an additional 1,852 shares during the period. UMB Bank n.a. boosted its holdings in shares of Regeneron Pharmaceuticals by 11.4% during the second quarter. UMB Bank n.a. now owns 898 shares of the biopharmaceutical company’s stock worth $944,000 after acquiring an additional 92 shares during the period. Finally, F M Investments LLC bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $7,050,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN traded up $5.76 during trading on Friday, hitting $1,184.69. 405,354 shares of the company were exchanged, compared to its average volume of 467,334. The business’s 50 day moving average is $1,100.29 and its 200-day moving average is $1,010.55. The company has a market capitalization of $130.54 billion, a P/E ratio of 35.00, a price-to-earnings-growth ratio of 3.12 and a beta of 0.13. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter in the previous year, the firm posted $8.79 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% on a year-over-year basis. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research analyst reports. TD Cowen boosted their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Morgan Stanley reduced their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 24th. Finally, Argus lifted their price target on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $1,108.45.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. The disclosure for this sale can be found here. Insiders have sold a total of 22,239 shares of company stock valued at $23,933,880 over the last 90 days. 7.48% of the stock is owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.